Treatment and costs associated with anemic chronic kidney disease patients

Current Medical Research and Opinion

Volumn 24, Issue 1, 2008, Pages 129-137

  Rasu, Rafia S ^a   Crawford, Tonya ^a   Manley, Harold ^b   Balkrishnan, Rajesh ^c  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Anemia; Health care costs; Kidney diseases; Quality of life

Indexed keywords

ERYTHROPOIETIN; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; IRON DEXTRAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON STORAGE; LABORATORY TEST; POSTMENOPAUSE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 38549100652     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X242782     Document Type: Review

References (60)

1. US Renal Data System. USRDS 2003 annual data report: atlas of end-stage renal disease in the United States. Bethesda MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2003
2. Kausz AT, Steinberg EP, Nissenson AR, et al. Prevalence and management of anemia among patients with chronic kidney disease in a health maintenance organization. Dis Manag Health Outcomes 2002;10:505-13
3. Nurko S. Anemia in chronic kidney disease: causes, diagnosis, treatment. Cleve Clin J Med 2006;73:289-97
4. National Kidney Foundation. K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001;37:S182-238
5. McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004;20:1501-10
6. Berns JS. Should all patients with chronic kidney disease receive an EPO-type drug? Cleve Clin J Med 2006;73:298-300
7. Hayashi T, Suzuki A, Shoji T, et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in pre-dialysis patients with chronic renal failure. Am J Kidney Dis 2000;35:250-6
8. Pickett JL, Therberge DC, Brown WD, et al. Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis 1999;33:1122-30
9. Lim VS, DeGowin RL, Zavala D, et al. Recombinant human erythropoietin treatment in pre-dialysis patients. Ann Intern Med 1989;110:108-14
10. Berns JS. Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed? Semin Dialysis 2005;18:22-9
11. Obrador GT, Pereira BG. Anaemia of chronic kidney disease: an under-recognized and under-treated problem. Nephrol Dial Transplant 2002;17:S44-46
12. US Renal Data System: USRDS 2005 annual data report: atlas of end-stage renal disease in United States. Bethesda MD: National Institutes of Health. Available from http://www.usrds.org/atlas.htm [Last accessed 23 June 2006]
13. US Renal Data System, USRDS 2000 Annual data report: atlas of end-stage renal disease in the United States. In: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda MD, 2000
14. Joy MS. Darbepoetin alfa: a novel erythropoiesis-stimulation protein. Ann Pharmacother 2002;36:1183-97
15. Lacombe C, Da Silva JL, Bruneval P, et al. Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J Clin Invest 1988;81:620-3
16. Erslev AJ, Besarab A. Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure. Kidney Int 1997;51:622-30
17. National Kidney Foundation. K/DOQI clinical practice guidelines for anemia of chronic kidney disease. Am J Kidney Dis 2006;47:S17-132
18. National Kidney Foundation releases preliminary anemia guideline update. Available from http://www.kidney.org/news/newsroom/newsitem.cfm?id=380 [Last accessed 1 Oct 2007]
19. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med 2003;228:1-14
20. Egrie JC, Strickland TW, Lane J, et al. Characterization and biological effects of recombinant human erythropoietin. Immunobiology 1986;172:213-24
21. Macdougall IC. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001;16:14-21
22. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulation protein (NESP). Br J Cancer 2001;84(Suppl 1):3-10
23. Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999;10:2392-95
24. Robinson DM, Easthope SE. Darbepoetin alfa: its use in anemia associated with chronic kidney disease. Biodrugs 2005;19:327-43
25. Overbay DK, Manley HJ. Darbepoetin-alpha: a review of the literature. Pharmacotherapy 2002;22:889-97
26. Goodnourgh LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood 2000;96:823-33
27. Hudson JQ, Comstock TJ. Considerations for optimal iron use for anemia due to chronic kidney disease. Clin Ther 2001;23:1637-71
28. Roe DJ, Harfod AM, Zager PG, et al. Iron utilization after iron dextran administration for iron deficiency in patients with dialysis-associated anemia: a prospective analysis and comparison of two agents. Am J Kidney Dis 1996;28:855-60
29. Charytan C, Qunibi W, Bailie GR. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract 2005;100:55-62
30. Hansen CM. Oral Iron supplements: choosing a product depends on elemental iron content, cost, and additives. Am Pharm 1994;34:66-71
31. Koury ST, Bondurant MC, Koury MJ, et al. Localization of cells producing erythropoietin in murine liver by in situ hybridization. Blood 1991;77:2497-503
32. Cournoyer D, Toffelmire EB, Wells GA, et al. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. J Am Soc Nephrol 2004;15:2728-34
33. Howman R, Kulkarni H. Antibody-mediated acquired pure red cell aplasia (PRCA) after treatment with darbepoetin. Nephrol Dial Transplant 2007;22:1462-4
34. Epoetin alpha recombinant package insert. Available from http://www.epogen.com [Last accessed 7 Aug 2006]
35. Darbepoetin alfa (Aranesp) package insert. Available from http://www.aranesp.com/professional/ckd/pi/pi.jsp [Last accessed 17 Sep 2001]
36. Macdougall IC. Novel erythropoiesis stimulating protein. Semin Nephrol 2000;20:375-81
37. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98
38. National Kidney Foundation. NKF-K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43:S1-268
39. Macdougall IC. The role of ACE inhibitors and angiotensin II receptor blockers in response to epoetin. Nephrol Dial Transplant 1999;14:1836-41
40. Hirakata H, Onoyama K, Iseki K, et al. Worsening of anemia induced by long-term use of captopril in hemodialysis patients. Am J Nephrol 1984;4:355-60
41. Vlahakos DV, Canzanello VJ, Madaio MP, et al. Enalapril-associated anemia in renal transplant recipients treated for hypertension. Am J Kidney Dis 1991;17:199-205
42. Kamper A-L, Nielsen OJ. Effect of enalapril on haemoglobin and serum erythropoietin in patients with chronic nephropathy. Scand J Clin Lab Invest 1990;50:611-8
43. Azizi M, Rousseau A, Ezan E, et al. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest 1996;97:839-44
44. Albitar S, Genin R, Fen-Chong M, et al. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant 1998;13:1206-10
45. Sanchez JA. ACE inhibitors do not increase r-HuEPO response in patients with end-stage renal failure. Nephrol Dial Transplant 1995;10:1476-7
46. Olin BR, editor. Drug facts and comparisons. St. Louis: J.B. Lippincott and Co, 1992. pp.62-6
47. Agarwal R, Warnock D. Issues related to iron replacement in chronic kidney disease. Semin Nephrol 2002;22:479-87
48. Bailie GR, Johnson CA, Mason NA. Parental iron use in the management of anemia in end-stage renal disease patients. Am J Kidney Dis 2000;35:1-12
49. Auerbach M, Witt D, Toler W, et al. Clinical use of total dose intravenous infusion of iron dextran. J Lab Clin Med 1988;111:566-70
50. Michael B, Coyne DW, Fishbance S, et al. Sodium ferric gluconate complex in hemodialysis patient: adverse reactions compared to placebo and iron dextran. Kidney Int 2002;61:1830-9
51. Van Wyck DB, Cavallo G, Spinowitz BS, et al. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Am J Kidney Dis 2000;36:88-97
52. Allon M, Kleinman K, Walczyk M, et al. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Clin Pharmacol Ther 2002;72:546-55
53. Nissenson AR, Swan SK, Lindberg JS, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002;40:110-8
54. Agarwal AK, Silver MR, Reed JE, et al. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis. J Intern Med 2006;260:577-85
55. Steinbrook R. Medicare and erythropoietin. N Engl J Med 2007;356:4-6
56. Anderson ER, Gibson G. Consideration in darbepoetin alfa cost and reimbursement: a model for pharmacy managers. Pharmacotherapy 2003;23:119S-24
57. Glapsy JA. Overcoming barriers to erythropoietic therapy. Oncology 2002;16:S71-7
58. Brophy DF, Ripley E, Kockler DR, et al. Darbepoetin Alfa therapeutic interchange protocol for anemia in dialysis. Ann Pharmacother 2005;39:1808-11
59. Micromedex® Healthcare Series. Thomson Micromedex, Greenwood Village, CO, USA. Available from http://www.thomsonhc.com [Last accessed 9 Aug 2006]
60. 2006 Drug Topics Red Book. Montvale, MJ: Thomson PDR, 2006